EGFR, frequently overexpressed or mutated in GBM, particularly in the EGFRvIII variant, is associated with aggressive tumor behavior and poor survival outcomes, although therapies targeting EGFR have had limited success [56]. This evidence concerns the gene EGFR and neoplasm.